检索结果-南通市图书馆

深部浸润低恶性MALT结肠淋巴瘤在抗生素治疗后的消退:超声内镜评估

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（胃肠病学分册） 2006年第1期2卷 52-52页

作者： Kikuchi Y. Matsui T. Hisabe T. 廖新华 Department of Gastroenterology Fukuoka University Chikushi Hospital 377-1 Ohaza Zokumyoin Chikushino 818-5807 Japan

Since 1997 we have experienced three cases of low-grade colonic mucosal-associated lymphoid tissue (MALT) lymphomas. The depth of tumor invasion was evaluated by endoscopic ultrasonography (EUS) and the mass lesions were all diagnosed as having extended beyond the deep region of the submucosal layer. Although all of these patients tested negative for gastric Helicobacter pylori, their tumor lesions regressed after antibiotic treatment in accordance with H. pylori eradication therapy. In general, consensus has been reached regarding antibiotic therapy for gastric MALT lymphomas. However, as a prerequisite for antibiotic therapy, the therapy has been deemed effective against these gastric tumors if the extent of infiltration, as evaluated by EUS, is limited to the mucosal layer or the superficial region of the submucosal layer. Based on the therapeutic outcomes seen in the three patients studied here, it is suggested that antibiotic therapy might be useful in treating MALT lymphomas of the colon, even in patients with advanced invasive tumors, in contrast to the extent of the lesions in the stomach suitable for antibiotic treatment. The success of the antibiotic treatment also suggests that MALT lymphomas may be caused by unknown luminal microorganisms, other than H. pylori.

关键词：结肠淋巴瘤 MALT 超声内镜浸润范围胃肿瘤黏膜层肿瘤浸润深度浸润性肿瘤胃幽门螺杆菌患

在线全文

学校读者我要写书评

暂无评论

原发于结膜的恶性淋巴瘤2例

中国临床医生杂志 2000年第9期28卷 30-31页

作者：侯秀玉李高峰高鸿肖素华刘明远北京医院放疗科 100730

6-巯基嘌呤治疗炎症性肠病的单中心10年治疗经验

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（胃肠病学分册） 2005年第7期1卷 40-41页

作者： Glazier K.D. Palance A.L. Griffel L.H. Das K.M. 樊菁 UMDNJ- Robert Wood Johnson Med. Sch. 1 Robert Wood Johnson Place New Brunswick NJ 08903 United States Dr.

Goals: To report the 10- year experience of a single center in treating pati ents with refractory inflammatory bowel disease (IBD) with relatively lower dose of 6- mercaptopurine (6- MP). Study: The charts of 285 patients with IBD (Cro hn’ s disease 160 and ulcerative colitis 125) receiving 6- MP were reviewed. C linical response, subsequent breakthrough while taking 6- MP, and relapse rates when 6- MP was discontinued and side effects were assessed. Results: Ninety- three percent of the patients were taking 50 to 75 mg/day of 6- MP. Complete re mission was achieved in 62% , partial remission in 14.5% , and failure to achi eve remission in 23.5% of the patients. Of complete responders, 27.5% had br eakthrough while continuing 6- MP. Nine percent of those that achieved a comple te remission experienced a relapse after 6- MP was discontinued. Side effects i ncluded leukopenia (11.2% ), abnormal liver function tests (3.8% ), various in fections, including pneumonia (3.1% ), pancreatitis (2.5% ), nausea (2.1% ), headache (2.8% ), fever (1.4% ), hair loss (1% ), and rash (0.7% ). Two canc ers occurred while taking 6- MP: melanoma on the finger and a fatal colonic lym phoma. Four patients continued 6- MP throughout pregnancies and had normal outc omes. Conclusions: In our experience 6- MP is relatively safe and appears to be as effective at a lower dosage (0.84 mg/kg per day) compared with the recommend ed higher dosage (1- 1.5 mg/kg per day), when leukopenia was more frequent. Ser ious side effects, although rare, need to be monitored.

关键词：炎症性肠病单中心克罗恩病溃疡性结肠炎结肠淋巴瘤临床反应复发率黑色素瘤白细胞减少正常分娩

在线全文

学校读者我要写书评

暂无评论

右下腹包块的影像学诊断